News

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 16, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 2, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Rhopressa® (netarsudil ophthalmic solution) 0.02% Label
Toggle Summary Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
Product Approved Ahead of the Scheduled PDUFA Date of February 28, 2018 IRVINE, Calif. --(BUSINESS WIRE)--Dec. 18, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 1, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 27, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 16, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast Today, November 8 th , at 5:00 p.m. ET IRVINE, Calif. --(BUSINESS WIRE)--Nov. 8, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 7, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye,
View HTML